CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...
EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 ---- Phase 3 PREVAIL CVOT overall event rate ...
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments ...
Zacks Small Cap Research on MSN
ARWR: Encouraging early data for obesity programs
ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Encouraging Early Data for Obesity Programs On January 6, 2026, ...
Stian Lydersen dr.ing. and professor of medical statistics at the Regional Centre for Child and Youth Mental Health and Child Welfare (RKBU Central Norway) at the Department of Mental Health, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback